WYSZOMIERSKI JACK L

SEC source: 0001193125-26-303724 · ownership.xml · derivative · entry 9

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,967 shares

Expires 2033-05-17

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F5 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303724 · ownership.xml · derivative · entry 8

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,996 shares

Expires 2032-05-18

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F5 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303724 · ownership.xml · derivative · entry 7

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,101 shares

Expires 2031-05-19

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F5 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303724 · ownership.xml · derivative · entry 6

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,152 shares

Expires 2030-05-20

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F5 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303724 · ownership.xml · derivative · entry 5

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,167 shares

Expires 2029-05-16

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F5 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303724 · ownership.xml · derivative · entry 4

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,052 shares

Expires 2028-05-17

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F5 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303724 · ownership.xml · derivative · entry 3

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,366 shares

Expires 2027-09-15

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F5 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303724 · ownership.xml · derivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires 2027-02-10

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.

F5 · derivative.exercise_date: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.

SEC source: 0001193125-26-303724 · ownership.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F2 · shares: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration").

F3 · shares: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.

F2 · price: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration").

F3 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.

SEC source: 0000939767-26-000085 · wk-form4_1780527122.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 284,384

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.

F2 · balance_after: Includes 8,367 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

SEC source: 0000939767-26-000076 · wk-form4_1780090989.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,309

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.

F2 · balance_after: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.

SEC source: 0001214659-26-006749 · marketforms-73268.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,116

F1 · shares: Consists of 3,586 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest in equal parts on a monthly basis, for 12 months from the date of grant, subject to the reporting person's continued service to the Company through such vesting date.

SEC source: 0001104659-26-061436 · tm2614699-7_4seq1.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,120

F1 · shares: Represents deferred stock units granted as director fees. The deferred stock units vest in full upon the earlier of (i) the day preceding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 13, 2026. Settlement is deferred until the earlier of the Reporting Person's termination of board service and a change in control of the Company.

F2 · balance_after: Includes deferred stock units.

SEC source: 0001214659-26-003848 · marketforms-72748.xml · derivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,026 shares

Expires 2026-07-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option became fully vested and exercisable as of July 21, 2017.

SEC source: 0001214659-26-003848 · marketforms-72748.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,530

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-26-000030 · wk-form4_1771637788.xml · derivative · entry 3

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,634 shares

Expires 2026-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 20,634 shares of Common Stock, became fully exercisable on May 23, 2019.

SEC source: 0000939767-26-000030 · wk-form4_1771637788.xml · nonDerivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 279,942

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.32 to $44.49. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F1 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

SEC source: 0000939767-26-000030 · wk-form4_1771637788.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 379,516

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

SEC source: 0000939767-25-000098 · wk-form4_1749081442.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 358,882

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $42.70 to $43.49. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

SEC source: 0000939767-25-000090 · wk-form4_1748646811.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,417

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 29, 2026, subject to the Reporting Person's continuous service through that date.

F2 · balance_after: Includes 28,650 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.

SEC source: 0001214659-25-008323 · marketforms-69664.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,504

F1 · shares: Consists of 5,971 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest on the first anniversary of the grant date, subject to the reporting person's continued service to the Company through such vesting date.

SEC source: 0001104659-25-050008 · tm2515380-3_4seq1.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,934

F1 · shares: Represents deferred stock units granted as director fees. The deferred stock units vest in full upon the earlier of (i) the day preceding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 14, 2025. Settlement is deferred until the earlier of the Reporting Person's termination of board service and a change in control of the Company.

F2 · balance_after: Includes deferred stock units.

SEC source: 0000939767-25-000039 · wk-form4_1740792881.xml · derivative · entry 3

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,874 shares

Expires 2025-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,874 shares of Common Stock, became fully exercisable on May 24, 2018.

SEC source: 0000939767-25-000039 · wk-form4_1740792881.xml · nonDerivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,605

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2024.

F1 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

SEC source: 0000939767-25-000039 · wk-form4_1740792881.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 365,373

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

SEC source: 0000939767-24-000103 · wk-form4_1717720669.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 349,499

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2024.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.88 to $22.15. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock.

SEC source: 0000939767-24-000097 · wk-form4_1717546800.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,786

F1 · date: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date.

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date.

F2 · balance_after: Includes 39,556 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of RSUs. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock.

SEC source: 0001214659-24-009519 · marketforms-65900.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,533

F1 · shares: Consists of 6,070 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest on the first anniversary of the grant date, subject to the reporting person's continued service to the Company through such vesting date.

SEC source: 0000939767-24-000063 · wk-form4_1715816662.xml · derivative · entry 3

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,686 shares

Expires 2024-05-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 11,686 shares of Exelixis, Inc. common stock, became fully exercisable on May 25, 2017.

SEC source: 0000939767-24-000063 · wk-form4_1715816662.xml · nonDerivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 338,948

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2024.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.30 to $21.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

F1 · balance_after: Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-24-000063 · wk-form4_1715816662.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 349,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001104659-24-059544 · tm2414046-8_4seq1.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,809

F1 · shares: Represents deferred stock units granted as director fees. The deferred stock units vest in full upon the earlier of (i) the day preceding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 7, 2024. Settlement is deferred until the earlier of the Reporting Person's termination of board service and a change in control of the Company.

F2 · balance_after: Includes deferred stock units.

SEC source: 0000939767-23-000057 · wk-form4_1685754957.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,185

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on June 1, 2024, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001214659-23-007562 · marketforms-61571.xml · derivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,967

Underlying: Common Shares · 10,967 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 17, 2023), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option.

SEC source: 0001104659-23-061027 · tm2315805d6_4seq1.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,944

F1 · shares: Represents deferred stock units granted as director fees. The deferred stock units vest in full upon the earlier of (i) the day preceding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 11, 2023. Settlement is deferred until the earlier of the Reporting Person's termination of board service and a change in control of the Company.

F2 · balance_after: Includes deferred stock units.

SEC source: 0000939767-23-000031 · wf-form4_167883973386085.xml · derivative · entry 3

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2023-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016.

SEC source: 0000939767-23-000031 · wf-form4_167883973386085.xml · nonDerivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,467

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 8, 2023.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.52 to $16.70. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-23-000031 · wf-form4_167883973386085.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,767

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 19,575 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001368148-23-000015 · wf-form4_167345809212193.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,141

F1 · shares: Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors.

SEC source: 0001368148-22-000137 · wf-form4_166369598257463.xml · derivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,042

Underlying: Common Stock · 32,042 shares

Expires 2032-09-16

F3 · derivative.exercise_date: Represents the exempt acquisition of stock options to purchase 32,042 shares of the Issuer's Common Stock at a per share exercise price of $1.95. These stock options in general will vest on July 28, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors.

SEC source: 0001368148-22-000137 · wf-form4_166369598257463.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,820

F1 · shares: Represents the exempt acquisition of 12,820 restricted stock units that in general will vest in total on December 31, 2022, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors.

F2 · balance_after: On August 26, 2022, the Issuer effected a 1-for-25 reverse stock split of its Common Stock (the "Reverse Stock Split").

SEC source: 0000939767-22-000074 · wf-form4_165369717131766.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,767

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 26, 2023, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 19,575 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001214659-22-007241 · marketforms-56244.xml · derivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,996

Underlying: Common Shares · 8,996 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 18, 2022), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option.

SEC source: 0001104659-22-060367 · tm2215518-10_4seq1.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,066

F1 · shares: Represents deferred stock units granted as director fees. The deferred stock units vest in full upon the earlier of (i) the day proceeding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 11, 2022. Settlement is deferred until the earlier of the reporting person's termination of board service and a change in control of the Company.

F2 · balance_after: Includes deferred stock units.

SEC source: 0000939767-22-000042 · wf-form4_164929012170594.xml · derivative · entry 3

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2022-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015.

SEC source: 0000939767-22-000042 · wf-form4_164929012170594.xml · nonDerivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,192

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2022.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.86 to $23.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-22-000042 · wf-form4_164929012170594.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,888

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 8,299 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0001368148-21-000080 · wf-form4_162379452842189.xml · derivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period.

SEC source: 0000939767-21-000067 · wf-form4_162224865729824.xml · derivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,598

Underlying: Common Stock · 16,598 shares

Expires 2028-05-26

F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date.

SEC source: 0000939767-21-000067 · wf-form4_162224865729824.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 239,888

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 8,299 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.